At a glance
ClinicalIndex Comparison RecordN/ACompleted· 18 enrolled
Drug / intervention
Verion-LenSxprocedure
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Pseudophakic Astigmatic Reduction With Verion-LenSx Arcuate Incisions
In Brief
A clinical study evaluating Verion-LenSx for Astigmatism. Completed, enrolled 18 participants across 1 site.
Detailed Summary
To assess the effectiveness of the Verion-LenSx guided arcuate incision technique to reduce astigmatism in a pseudophakic population.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAstigmatism
CountriesUnited States
CollaboratorsAlcon, a Novartis Company
Timeline
N/ACompletedFinished
2017201820192020202120222023202420252026
Enrollment StartMay 2016
First PostedMay 2016
Primary CompletionOct 2016
TodayJul 2026
First PostedMay 5, 2016
Enrollment StartMay 1, 2016
Primary CompletionOct 1, 2016
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 10.2 years ago
Interventions
Verion-LenSxprocedure
The Verion-LenSx femtosecond laser system will be used to create one or two partial-depth corneal arcuate incisions